More on AI: When it comes to folding AI tools into mammograms, AI firms believe there’s even more knowledge to be gleaned ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of high unmet need, ...

Dilon Technologies, a leading provider of medical devices, has gained FDA approval for its MarginProbe® 2 system and is announcing its launch in the U.S. This is the next-generation device for ...

Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one ...

The phase 3 MajesTEC-3 trial demonstrated that the combination of the bispecific BCMA-directed T-cell engager teclistamab and ...

There is still time to complete key health screenings before the end of the year, and Check Up 13 is making it easier than ever.

A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an ...

A digital toolkit with patient scripts, risk calculator comparisons and more could help primary care and OB/GYN providers ...

In non-low-risk DCIS of the breast, the addition of a TBB of radiation following postoperative WBI is associated with reduced local recurrence.

Innovative smart pill bottles significantly enhance adherence to oral adjuvant endocrine therapy in early-stage breast cancer ...

Some experts believe the cancer label can be inappropriate for certain low-risk conditions and advocate dropping the C-word.

The test is now ordered by breast surgeons or radiation oncologists in more than 85% of the top 50 U.S. cancer centers.